Relacorilant (Lifyorli) coverage for platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.736 alerts
Get alerted when Policy CP.PHAR.736 changes without checking for updates manually.
Monitor payer policy activity
This policy defines medical necessity and prior authorization criteria for relacorilant (Lifyorli) when used in combination with nab‑paclitaxel for adults with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, and provides continuation, dosing, contraindication, and related guidance affecting commercial, HIM/ICHRA, and Medicaid lines of business.
Criteria added for the new FDA‑approved indication of relacorilant (Lifyorli) for platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with nab‑paclitaxel.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.